2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research 2019, 25: 6382-6391. PMID: 31182434, PMCID: PMC6825535, DOI: 10.1158/1078-0432.ccr-19-0780.Peer-Reviewed Original Research
2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.Peer-Reviewed Case Reports and Technical Notes
2017
Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma
Benedict M, Rodriguez-Davalos M, Emre S, Walther Z, Morotti R. Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma. Pediatric And Developmental Pathology 2017, 20: 354-362. PMID: 28727971, DOI: 10.1177/1093526616686458.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsCarcinoma, HepatocellularCongenital AbnormalitiesHumansInfantLiverLiver NeoplasmsLiver TransplantationMalePortal VeinTreatment OutcomeConceptsAbernethy malformationCongenital portosystemic shuntsHepatocellular carcinomaPortosystemic shuntPortal veinVena cavaCongenital absenceCongenital extrahepatic portosystemic shuntAssociated Hepatocellular CarcinomaSplanchnic venous systemNodular regenerative hyperplasiaExtrahepatic portosystemic shuntSmall hepatocellular carcinomaFocal nodular hyperplasiaRegenerative hyperplasiaClinical manifestationsImmunohistochemical characteristicsIntrahepatic shuntsLiver adenomasTypical presentationPortal bloodNodular hyperplasiaVenous systemComplete diversionResult of malformation
2009
Isospora cholangiopathy: case study with histologic characterization and molecular confirmation
Walther Z, Topazian MD. Isospora cholangiopathy: case study with histologic characterization and molecular confirmation. Human Pathology 2009, 40: 1342-1346. PMID: 19447468, DOI: 10.1016/j.humpath.2009.01.020.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnimalsAnti-Infective AgentsAntiparasitic AgentsBile Ducts, ExtrahepaticBile Ducts, IntrahepaticBiopsyCholangiopancreatography, Endoscopic RetrogradeCholangitis, SclerosingHumansIsosporaIsosporiasisIvermectinMalePolymerase Chain ReactionTreatment OutcomeTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAIDS patientsBile ductIsospora belliCommon bile duct biopsiesPolymerase chain reaction-based molecular analysisBile duct biopsyPrimary sclerosing cholangitisExtrahepatic bile ductRare opportunistic pathogenEndoscopic retrograde cholangiopancreatographyIntracellular protozoan parasiteDuct biopsySclerosing cholangitisUncommon causeAcute illnessHIV statusRadiologic findingsRetrograde cholangiopancreatographyTravelers' diarrheaWest African menHepatobiliary diseaseHistologic characterizationSmall intestineDiarrheaIsosporiasis